GCP
AMRX icon

GSA Capital Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

GSA Capital Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,657
Closed -$273K – 1685
2025
Q4 		$273K Sell
21,657
-38,893
-64% -$445K 0.02% 1219
2025
Q3 		$606K Buy
60,550
+23,668
+64% +$212K 0.05% 721
2025
Q2 		$298K Sell
36,882
-33,532
-48% -$253K 0.02% 1254
2025
Q1 		$590K Sell
70,414
-1,687
-2% -$14.1K 0.05% 677
2024
Q4 		$571K Buy
72,101
+17,751
+33% +$149K 0.04% 784
2024
Q3 		$452K Sell
54,350
-100,410
-65% -$785K 0.03% 972
2024
Q2 		$983K Sell
154,760
-28,202
-15% -$179K 0.07% 510
2024
Q1 		$1.11M Buy
+182,962
New +$1.03M 0.09% 375
2023
Q4 		– Sell
-22,986
Closed -$97K – 1470
2023
Q3 		$97K Sell
22,986
-91,265
-80% -$340K 0.01% 1390
2023
Q2 		$354K Buy
114,251
+33,732
+42% +$71.9K 0.04% 950
2023
Q1 		$112K Sell
80,519
-94,530
-54% -$188K 0.01% 1344
2022
Q4 		$348K Buy
+175,049
New +$392K 0.04% 834
2022
Q3 		– Sell
-151,865
Closed -$483K – 1483
2022
Q2 		$483K Buy
151,865
+43,891
+41% +$159K 0.07% 526
2022
Q1 		$450K Buy
107,974
+74,572
+223% +$330K 0.06% 608
2021
Q4 		$160K Buy
+33,402
New +$167K 0.02% 1262
2021
Q3 		– Sell
-111,200
Closed -$569K – 1396
2021
Q2 		$569K Buy
111,200
+86,333
+347% +$491K 0.06% 548
2021
Q1 		$167K Sell
24,867
-14,685
-37% -$81.4K 0.03% 942
2020
Q4 		$181K Sell
39,552
-14,312
-27% -$63.4K 0.03% 1019
2020
Q3 		$209K Buy
53,864
+3,963
+8% +$16.9K 0.03% 981
2020
Q2 		$238K Sell
49,901
-48,338
-49% -$199K 0.13% 261
2020
Q1 		$342K Buy
+98,239
New +$416K 0.09% 403
2019
Q3 		– Sell
-51,264
Closed -$368K – 1377
2019
Q2 		$368K Buy
+51,264
New +$524K 0.04% 860
2019
Q1 		– Sell
-17,343
Closed -$235K – 1410
2018
Q4 		$235K Buy
+17,343
New +$313K 0.03% 999

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

GSA Capital Partners's AMRX Position: Q1 2026 in Review

GSA Capital Partners sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 21,657 shares — an estimated $273K sold.

GSA Capital Partners first reported a position in AMRX in Q4 2018 and held it in 23 quarters. The position peaked at $1.11M in Q1 2024. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • GSA Capital Partners reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 21,657 Amneal Pharmaceuticals shares in Q1 2026, an estimated $273K.
  • GSA Capital Partners first reported a position in Amneal Pharmaceuticals in Q4 2018 and held it in 23 quarters.
  • GSA Capital Partners's Amneal Pharmaceuticals position peaked at $1.11M in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.